ABSTRACT: OBJECTIVE: The study aims to conduct a rapid systematic evaluation of antiviral treatments in Critical Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS), and to explore the clinical possibility of subcutaneous injection of alpha-interferon for the 2019 novel coronavirus (2019-NCoV) pneumonia Journal Full Text Database (CNKI), Wip Chinese Science and Technology Journal Full-Text Database (VIP), Wanfang Database (Wangfang Data), Chinese Biomedical Literature Database (CBM), Cochrane library, PubMed etc.. In addition, retrieving WHO and CDC websites, National Health Commission websites, relevant national releases Diagnostic regimens (c) Evidence evaluation and data extraction according to evidence-based pharmacological methods obtained 1502 articles were retrieved and eventually included in 11 studies. Results suggest: ① Early use of subcutaneous injection alpha-interferon, as far as possible in the confirmed coronavirus After infection 48 h use, with the extension of the time of medication and the time of diagnosis, effective Reduced, so treatment as early as possible .2. No statistically significant difference in treatment effect between various types of interferon .3. Subcutaneous injection of alpha-interferon in combination with ribavirin has been proven effective in individual studies, but need to be wary of its adverse reaction. adverse reactions are more tolerable to drop in hemoglobin, elevated transaminasinases, Amylase is elevated, but most do not affect treatment. concluded that subcutaneous injection of alpha-interferon can be used as a Experimental therapies are used in antiviral treatment of novel coronavirus pneumonia, especially in newly infected persons, and randomized controlled trials and real-world clinical studies should be conducted as soon as possible to further explore the clinical effects of alpha-interferon for novel coronavirus pneumonia.
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been a focus of international attention since its identification in 2012. Epidemiologically it is characterized by sporadic community cases, which are amplified by hospital-based outbreaks. Healthcare facilities in 27 countries from most continents have experienced imported cases, with the most significant outbreak involving 186 cases in Korea. The mortality internationally is 36% and guidance for clinical management has yet to be developed. Most facilities and healthcare providers outside of the Middle East receiving patients have no or little experience in the clinical management of MERS. When a case does occur there is likely little time for a critical appraisal of the literature and putative pharmacological options. We identified published literature on the management of both MERS-CoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) through searches of PubMed and WHO and the US CDC websites up to 30 April 2016. A total of 101 publications were retrieved for critical appraisal. Most published literature on therapeutics for MERS are in vitro experiments, animal studies and case reports. Current treatment options for MERS can be categorized as: immunotherapy with virus-specific antibodies in convalescent plasma; polyclonal and monoclonal antibodies produced in vitro or in genetically modified animals; and antiviral agents. The use of any therapeutics in MERS-CoV remains investigational. The therapeutic agents with potential benefits and warranting further investigation include convalescent plasma, interferon-β/ribavirin combination therapy and lopinavir. Corticosteroids, ribavirin monotherapy and mycophenolic acid likely have toxicities that exceed potential benefits.
The study aims to conduct a rapid systematic evaluation of antiviral treatments in Critical Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS), and to explore the clinical possibility of subcutaneous injection of alpha-interferon for the 2019 novel coronavirus (2019-NCoV) pneumonia Journal Full Text Database (CNKI), Wip Chinese Science and Technology Journal Full-Text Database (VIP), Wanfang Database (Wangfang Data), Chinese Biomedical Literature Database (CBM), Cochrane library, PubMed etc.. In addition, retrieving WHO and CDC websites, National Health Commission websites, relevant national releases Diagnostic regimens (c) Evidence evaluation and data extraction according to evidence-based pharmacological methods obtained 1502 articles were retrieved and eventually included in 11 studies. Results suggest: ① Early use of subcutaneous injection alpha-interferon, as far as possible in the confirmed coronavirus After infection 48 h use, with the extension of the time of medication and the time of diagnosis, effective Reduced, so treatment as early as possible .2. No statistically significant difference in treatment effect between various types of interferon .3. Subcutaneous injection of alpha-interferon in combination with ribavirin has been proven effective in individual studies, but need to be wary of its adverse reaction. adverse reactions are more tolerable to drop in hemoglobin, elevated transaminasinases, Amylase is elevated, but most do not affect treatment. concluded that subcutaneous injection of alpha-interferon can be used as a Experimental therapies are used in antiviral treatment of novel coronavirus pneumonia, especially in newly infected persons, and randomized controlled trials and real-world clinical studies should be conducted as soon as possible to further explore the clinical effects of alpha-interferon for novel coronavirus pneumonia.
